A Prospective Single-Arm Feasibility Study of a Personalized Approach to the Inpatient Management of Hospitalized Oncology Patients with Hyperglycemia
The purpose of this study is to compare the outcomes between hospitalized cancer patients with high blood sugar receiving the current standard of care of administering insulin, and hospitalized cancer patients receiving a new, individualized method of insulin administration.
Primary Objective: To correctly implement the basal-prandial-correctional insulin protocol in hospitalized oncology patients in medical units, in order to achieve euglycemia.
Important Secondary Objectives: To demonstrate that the correct implementation of basal-prandial-correctional insulin in hospitalized Hispanic patients will reduce the disparity between outcomes for Hispanic and non-Hispanic patients, thereby closing a cancer health disparity gap.
Provision of signed and dated informed consent form
Stated willingness to comply with all study procedures and availability for the duration of the study
Provide race and ethnicity information
Male or female, aged 18 years or greater
Diagnosed with cancer
Hospitalized at MCC in the medical, hematologic, or bone marrow transplant units
Having in-hospital hyperglycemia with or without a pre-existing diagnosis of DM, with 2 measurements of BG > 180 mg/dL and/or 1 measurement of BG > 350mg/dL within the first 72 hours of admission, detected by bedside point-of-care testing and/or basic metabolic panel laboratory data.
Participants enrolled in other clinical trials are admissible to this trial.
An individual who meets any of the following criteria will be excluded from participation in this study:
Participants > Patients of non-Hispanic descent
Participants at the end of life and/or with limited life expectancies (>Participants without cancer diagnoses
Surgical participants and participants admitted directly to the intensive care unit, other than those in the Bone Marrow Transplant Unit, who are included
Participants treated and discharged in outpatient settings (ie, direct referral center, infusion center, or clinical research unit) or those admitted for observation only (hospitalized less than 24 hours)
Participants on total parenteral nutrition
Participants on insulin pumps
Participants admitted with diabetic ketoacidosis and hyperglycemic hyperosmolar syndrome
Pregnant participants based on medical history
Participants being followed by endocrinology for hyperglycemia or hypoglycemia
Please call 1-888-663-3488 for support from a Moffitt representative. New Patients and Healthcare Professionals can submit an online form by selecting the appropriate buttonbelow. Existing patients can call 1-888-663-3488. Click here for a current list of insurances accepted at Moffitt.
NEW PATIENTS To request a new patient appointment, please fill out the online form or call 1-888-663-3488.
REFERRING PHYSICIANS Providers and medical staff can refer patients by submitting our online referral form.
Moffit now offers Virtual Visits for patients. If you are eligible for a virtual appointment, our scheduling team will discuss this option further with you.
Moffitt Cancer Center is committed to the health and safety of our patients and their families. For more information on how we’re protecting our new and existing patients, visit our COVID-19 Info Hub